Myopia cell discovered in retina
By www.sciencedaily.com
Northwestern Medicine scientists have discovered a cell in the retina that may cause myopia when it dysfunctions. The dysfunction may be linked to the amount of time a child spends indoors and away from natural light.
"This discovery could lead to a new therapeutic target to control myopia," said Greg Schwartz, lead investigator and assistant professor of ophthalmology at Northwestern University Feinberg School of Medicine.
More than a billion people in the world have myopia, whose incidence is rising and is linked to how much time people spend indoors as children.
The newly discovered retinal cell - which is highly sensitive to light - controls how the eye grows and develops. If the cell instructs the eye to grow too long, images fail to be focused on the retina, causing nearsighted vision and a lifetime of corrective glasses or contact lenses.
"The eye needs to stop growing at precisely the right time during childhood," Schwartz said.
It has long been long known the retina contains a signal to focus the image in the eye, and this signal is important for properly regulating eye growth during childhood.
"But for years no one knew what cell carried the signal," Schwartz said. "We potentially found the key missing link, which is the cell that actually does that task and the neural circuit that enables this important visual function."
Schwartz named the cell, "ON Delayed," in reference to its slow responses to lights becoming brighter. The cell was unique among many other cell types tested in its exquisite sensitivity to whether an image was in focus.
He described the neural circuit as the diagram that reveals how this cell is wired to other cells in the retina to acquire this unique sensitivity.
How too much time indoors may trigger myopia
The indoor light spectrum has high red/green contrast, which activates these clusters of photoreceptors in the human eye, creating the equivalent of an artificial contrast image on the retina. It's likely the human version of the ON Delayed retinal ganglion cell would be overstimulated by such patterns, causing aberrant over-growth of the eye, leading to myopia, Schwartz said.
The study will appear in the Feb. 20 print issue of Current Biology. It was published online Jan. 26.
To conduct the study, Schwartz and co-author Adam Mani, a postdoctoral fellow in ophthalmology at Feinberg, used microscopic glass electrodes to record electrical signals from cells in a mouse retina while presenting patterns of light on a digital projector.
The next goal is to find a gene specific to this cell. Then scientists can turn its activity up or down in a genetic mouse model to try to induce or cure myopia.
The study is part of Schwartz's larger body of research to reverse engineer the retina by identifying new retinal cell types in mice. The retina has about 50 types of retinal ganglion cells, which together convey all the information we use to perceive the visual world. Each of these cells provides different visual information - such as color or motion - about any point in space.
Schwartz, who is funded by the National Institutes of Health (NIH), wants to identify the new cells by their specific function, analyze their genetic signatures and understand how the cells are interconnected within the retina and to their targets in the brain. His research could lead to gene therapy to treat blindness and to improve the function of artificial retinal prosthetics.
The article is titled "Circuit Mechanisms of a Retinal Ganglion Cell with Stimulus-Dependent Response Latency and Activation Beyond Its Dendrites."
Source: https://www.sciencedaily.com/releases/2017/02/170206150640.htm
Wednesday, May 13, 2026
Lisinopril: Brand Name Medication Guide For Blood Pressure Management
Lisinopril is the brand name for lisinopril, a medication used in the management of conditions associated with blood pressure management. Brand name medications are pharmaceutical products marketed under a proprietary name by the company that originally developed them. Understanding the relationship between brand name and generic formulations, as well as the conditions for which the medication is approved, helps patients make informed choices about their treatment. Antihypertensive medications work through several different mechanisms, and many patients eventually require two or more drugs to achieve adequate blood pressure control. Major classes include ACE inhibitors and ARBs, which relax blood vessels by blocking the renin-angiotensin system; calcium channel blockers, which reduce arterial stiffness; beta-blockers, which slow the heart rate and reduce its workload; and diuretics, which reduce blood volume by increasing fluid excretion through the kidneys. The brand name Lisinopril has built a clinical track record through use in a wide range of patients and healthcare settings. Brand versions and their generic equivalents contain the same active ingredient at the same strength, but may differ in inactive ingredients such as fillers, binders, and coatings. In most cases, generic formulations are therapeutically equivalent and offer cost savings, though some patients prefer to stay on a specific formulation for consistency. When prescribed Lisinopril, patients should follow the guidance of their prescribing physician regarding dose, frequency, and duration of therapy. The medication should be stored as directed on the label, typically at room temperature away from heat and moisture. Any unused medication should not be disposed of by flushing down the drain unless the label specifically says to do so, as this can harm the environment. Comprehensive details on Lisinopril and other medications used for blood pressure management are available through https://mednewwsstoday.com/blood-pressure/. This resource provides evidence-based summaries to help patients and healthcare providers stay informed about treatment options in this therapeutic area.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.